| Date | Price Target | Rating | Analyst |
|---|
Fastest customizable press release news feed in the world
DUBLIN, Dec. 2, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that it completed the previously announced acquisition of BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for $88.50 per share in an all-cash transaction, for an estimated enterprise value of approximately $540 million (net of approximately $120 million in cash acquired). "We're pleased to have completed the acquisition of BioSpecifics, which immediately enhances our adjusted EBITDA and the profitability profile of both XIAFLEX® and Qwo™—two of our most durable and differentiated products with significant long-term growth potential," said Blaise Coleman, President and
15-12B - BIOSPECIFICS TECHNOLOGIES CORP (0000875622) (Filer)
Live finance-specific insights
DUBLIN, Dec. 2, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that it completed the previously announced acquisition of BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for $88.50 per share in an all-cash transaction, for an estimated enterprise value of approximately $540 million (net of approximately $120 million in cash acquired). "We're pleased to have completed the acquisition of BioSpecifics, which immediately enhances our adjusted EBITDA and the profitability profile of both XIAFLEX® and Qwo™—two of our most durable and differentiated products with significant long-term growth potential," said Blaise Coleman, President and
This live feed shows all institutional transactions in real time.
SC 13G/A - BIOSPECIFICS TECHNOLOGIES CORP (0000875622) (Subject)
SC 13G/A - BIOSPECIFICS TECHNOLOGIES CORP (0000875622) (Subject)